Products for Research Use Only

Rosopatamab

CAT: 0804-HY-P99239-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99239-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency[1].
CAS Number
2260767-49-3
Product Name Alternative
HUJ-591; TLX591
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
PSMA; Radionuclide-Drug Conjugates (RDCs)
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rosopatamab.html
Purity
99.50
Solubility
10 mM in DMSO
Smiles
[Rosopatamab]
Molecular Weight
(144.11 kDa)
Precautions
H302, H315, H319, H335
References & Citations
[1]Antonini P, et al. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT) [J]. 2022.|[2]Johnstone CN, et al. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025 Jan 30:jnumed.124.268695.|[3]Johnstone C, et al. Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma. 2023.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
RDC Antibody

Popular Products